Pfizer Inc. (NYSE: PFE) has announced a significant breakthrough in its quest to capture a share of the $150 billion global obesity market. Topline results from the Phase 2b VESPER-3 study reveal that its investigational “ultra-long-acting” GLP-1 receptor agonist, PF-08653944 (formerly MET-097i), achieved robust weight loss with just one injection per month.
The data marks a pivotal moment for Pfizer, which has pivoted its metabolic strategy toward external acquisitions after setbacks with its internal oral drug candidates.
The Results: 12.3% Weight Loss in 28 Weeks
The VESPER-3 study evaluated adults with obesity or overweight without type 2 diabetes. Participants initially underwent a 12-week weekly titration phase before switching to a monthly maintenance dose.
Key findings include:
- Significant Weight Reduction: Patients on the medium monthly maintenance dose (4.8 mg) achieved a 12.3% placebo-adjusted weight loss at week 28.
- Continued Momentum: Unlike some therapies that see weight loss slow down during dosing transitions, Pfizer reported that weight loss continued steadily after switching from weekly to monthly injections, with no plateau observed by the 28-week mark.
- Safety Profile: The drug maintained a tolerability profile consistent with the GLP-1 class. Gastrointestinal side effects were “predominantly mild or moderate,” with a low discontinuation rate due to adverse events (roughly 4.6% across key monthly arms).
A Game-Changing Dosing Schedule
The “monthly” factor is the drug’s primary competitive edge. Currently, market leaders Wegovy (Novo Nordisk) and Zepbound (Eli Lilly) require weekly injections. By reducing the frequency of administration fourfold, Pfizer aims to improve patient compliance and convenience a major hurdle in long-term weight management.
These topline results from the Phase 2b VESPER-3 study reinforce the potential of PF’3944 as a monthly treatment with competitive efficacy,
Based on the monthly dosing efficacy and tolerability demonstrated in this trial, we remain confident in our plan to include a higher 9.6 mg monthly maintenance dose of PF’3944 in Phase 3. With PF’3944 as an anchor of Pfizer’s obesity pipeline, we are positioned to address critical gaps in obesity care and meet the diverse needs of patients.
Dr. Jim List
The Metsera Pivot: From Setback to Strategy
The success of PF-08653944 follows a period of uncertainty for Pfizer’s obesity pipeline. After the high-profile discontinuation of its in-house oral candidates danuglipron and lotiglipron due to liver toxicity concerns and high side-effect rates, Pfizer moved aggressively to acquire the technology.
The drug was the centerpiece of Pfizer’s $10 billion acquisition of Metsera in late 2025. By securing Metsera’s peptide engineering platform, Pfizer has not only gained a monthly injectable but also a suite of “next-generation” assets, including amylin analogs and GIPR agonists that could be used in future combination therapies.
The Road Ahead: 2026 Phase 3 Blitz
Pfizer is wasting no time in taking the fight to Lilly and Novo. The company plans to advance 10 separate Phase 3 trials for PF-08653944 in 2026, including:
- VESPER-4: Investigating weekly dosing (already underway).
- VESPER-6: Investigating the once-monthly dosing regimen for obesity.
- Comorbidity Studies: Additional trials targeting obesity-related conditions like type 2 diabetes and cardiovascular disease.
Market Implications
Detailed results from the VESPER-3 study are scheduled to be presented at the 86th Scientific Sessions of the American Diabetes Association (ADA) on June 6, 2026. For now, the “ultra-long-acting” data suggests that Pfizer’s $10 billion bet may be exactly the booster shot its portfolio needed.
Last Modified:
